

EAGLE PHARMACEUTICALS, INC.  
Form S-8  
March 20, 2017

As filed with the Securities and Exchange Commission on March 20, 2017

Registration No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

---

**EAGLE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation or organization)

**20-8179278**

(I.R.S. Employer Identification No.)

**50 Tice Boulevard, Suite 315**

**Woodcliff Lake, NJ**

(Address of Principal Executive Offices)

**07677**

(Zip Code)

---

**2014 Equity Incentive Plan**

**2014 Employee Stock Purchase Plan**

(Full titles of the plans)

---

**Scott Tarriff**

**Chief Executive Officer**

**Eagle Pharmaceuticals, Inc.**

**50 Tice Boulevard, Suite 315**

**Woodcliff Lake, NJ 07677**

**(201) 326-5300**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

**Copies to:**

**Marc Recht, Esq.**  
Cooley LLP  
500 Boylston Street, 14th Floor  
Boston, Massachusetts 02116  
(617) 937-2300

**David E. Riggs**  
Chief Financial Officer  
Eagle Pharmaceuticals, Inc.  
50 Tice Boulevard, Suite 315  
Woodcliff Lake, NJ 07677  
(201) 326-5300


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

|                         |                       |                           |                                  |
|-------------------------|-----------------------|---------------------------|----------------------------------|
| Large Accelerated filer | <input type="radio"/> | Accelerated filer         | <input checked="" type="radio"/> |
| Non-accelerated filer   | <input type="radio"/> | Smaller reporting company | <input type="radio"/>            |

(Do not check if a smaller reporting company)

---

**CALCULATION OF REGISTRATION FEE**



vision



**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,073,584 shares of Common Stock of Eagle Pharmaceuticals, Inc. (the Registrant ) issuable pursuant to the Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended and restated (the 2014 EIP ) and the Eagle Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan (the 2014 ESPP ). These additional shares of Common Stock are securities of the same class as other securities for which an original registration statement on Form S-8 (File No. 333-194056) was filed with the Securities and Exchange Commission (the Commission ) on February 21, 2014. These additional shares of Common Stock have become reserved for issuance as a result of the operation of the evergreen provisions in each of the 2014 EIP and the 2014 ESPP, which provide that the total number of shares subject to such plans will be increased each year pursuant to a specified formula.

**PART II**

**INCORPORATION OF DOCUMENTS BY REFERENCE**

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

The Registrant previously registered shares of its Common Stock for issuance under the 2014 EIP and the 2014 ESPP under Registration Statements on Form S-8 filed with the Commission on February 21, 2014 (File No. 333-194056), on September 2, 2015 (File No. 333-206729), and on September 16, 2016 (File No. 333-213683). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woodcliff Lake, State of New Jersey, on March 20, 2017.

**EAGLE PHARMACEUTICALS, INC.**

By: /s/ Scott Tarriff  
Scott Tarriff  
Chief Executive Officer and Director

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Scott Tarriff and David E. Riggs, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

| <b>Signature</b>                     | <b>Title</b>   | <b>Date</b>    |
|--------------------------------------|--|----------------|
| /S/ SCOTT TARRIFF<br>Scott Tarriff   | Chief Executive Officer<br>and Member of the Board of Directors<br>(Principal Executive Officer) | March 20, 2017 |
| /S/ DAVID E. RIGGS<br>David E. Riggs | Chief Financial Officer<br>(Principal Accounting and Financial Officer)                          | March 20, 2017 |
| /S/ MICHAEL GRAVES<br>Michael Graves | Chairman of the Board of Directors   | March 20, 2017 |
| /S/ STEVEN RATOFF<br>Steven Ratoff   | Member of the Board of Directors   | March 20, 2017 |
| /S/ SANDER FLAUM                     |  |                |

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form S-8

|  |                                  |                |
|--|----------------------------------|----------------|
| Sander Flaum                                       | Member of the Board of Directors | March 20, 2017 |
| /S/ ROBERT L. GLENNING<br>Robert L. Glenning       | Member of the Board of Directors | March 20, 2017 |
| /S/ DOUGLAS L. BRAUNSTEIN<br>Douglas L. Braunstein | Member of the Board of Directors | March 20, 2017 |
| Richard A. Edlin                                   | Member of the Board of Directors | March , 2017   |

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description</b>   |
|-----------------------|--|
| 4.1(1)                | Amended and Restated Certificate of Incorporation of the Registrant.             |
| 4.2(2)                | Amended and Restated Bylaws of the Registrant.                                   |
| 4.3(3)                | Form of Common Stock Certificate of the Registrant.                              |
| 5.1                   | Opinion of Cooley LLP.   |
| 23.1                  | Consent of BDO USA, LLP, an Independent Registered Public Accounting Firm.       |
| 23.2                  | Consent of Cooley LLP. Reference is made to Exhibit 5.1.                         |
| 24.1                  | Power of Attorney. Reference is made to the signature page hereto.               |
| 99.2(4)               | Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended and restated. |
| 99.3(5)               | Eagle Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan.                   |

---

(1) Previously filed as Exhibit 3.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

(2) Previously filed as Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

(3) Previously filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 28, 2014, and incorporated herein by reference.

(4) Previously filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-36306), filed with the Commission on August 10, 2015, and incorporated herein by reference.

(5) Previously filed as Exhibit 10.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-192984), filed with the Commission on January 22, 2014, and incorporated herein by reference.